Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
Edwards Lifesciences Corporation logo

NYSE · EW

Edwards Lifesciences Corporation

Healthcare · Medical - Devices

$88.26

Up+$0.01 (+0.01%)

Updated Sep 20, 2026, 8:34 AM

SID Score

6.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
49.46B
P/E ratio
36.1
Dividend yield
0.00%
52-week range
$74.66 – $96.29
Volume
4.26M
Avg. volume
4.51M

Price performance

EW price history

1M range · 19 trading sessions · Daily adjusted prices

EW closed at $88.26 after 19 trading sessions, down 2.48% for the selected period.

Last close
$88.26
Period change
-2.48%
Period low
$84.37
Period high
$90.87
Daily close
View OHLC price history
EW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$88.03$88.77$87.47$88.264.26M
Sep 17, 2026$89.21$89.5788$88.00$88.253.88M
Sep 16, 2026$84.99$89.70$84.84$89.285.01M
Sep 15, 2026$85.03$86.025$84.47$85.743.78M
Sep 14, 2026$85.45$86.26$85.12$85.522.99M
Sep 11, 2026$87.51$87.755$83.81$84.373.8M
Sep 10, 2026$86.00$87.27$85.00$86.772.31M
Sep 9, 2026$86.27$87.04$85.73$86.182.74M
Sep 8, 2026$89.07$89.095$86.39$86.723.58M
Sep 4, 2026$90.21$90.21$88.40$89.902.64M
Sep 3, 2026$91.08$91.53$89.33$89.781.84M
Sep 2, 2026$91.465$92.3568$90.55$90.822.6M
Sep 1, 2026$91.39$92.95$90.10$90.742.54M
Aug 31, 2026$91.00$91.29$89.315$90.754.05M
Aug 28, 2026$89.98$90.4099$89.55$90.212.04M
Aug 27, 2026$90.78$91.48$89.79$89.953.06M
Aug 26, 2026$90.29$92.12$90.08$90.782.78M
Aug 25, 2026$90.38$91.265$89.68$90.872.39M
Aug 24, 2026$89.885$91.11$89.46$90.502.72M

Latest EW news

The latest Smart Investors Daily articles mentioning EW.

Stock researchCompany · Overview

EW research

Overview

Company profile and research snapshot.

Company profile

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$95.40
Implied upside
—
Analysts
19
EW recent ratings
DateFirmRatingTarget
Sep 11, 2026BTIGBuy—
Jul 24, 2026Leerink PartnersOutperform—
Jul 24, 2026Piper SandlerOverweight—
Jul 24, 2026JP MorganOverweight—
Jul 16, 2026Truist SecuritiesHold—
Open full forecast

News briefing

Generated Sep 20, 2026, 11:21 AM

Why Is EW Moving Sideways Today?

Edwards Lifesciences stock is essentially flat today as investors digest news regarding the company's expanded transcatheter aortic valve replacement (TAVR) access following a Medicare coverage decision. The muted price action suggests the market is taking a measured approach to what could be a significant long-term growth opportunity for the medical device maker.

    Bottom line: Edwards Lifesciences' expanded TAVR access represents a meaningful positive development, but today's flat price action suggests the market has modestly priced in these benefits. Investors should monitor upcoming earnings reports and management guidance to determine whether the company can exceed consensus expectations and unlock additional shareholder value from this market expansion.

    Yahoo · Sep 18, 2026

    How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions

    Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...

    Yahoo · Sep 18, 2026

    Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

    Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...

    Yahoo · Sep 17, 2026

    Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

    Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By